atorvastatin has been researched along with Focal Segmental Glomerulosclerosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernabei, E; Caramiello, MS; Centi, A; Di Franco, D; Di Vasta, G; Dominijanni, S; Guido, G; Londrino, F; Palumbo, R; Tatangelo, P | 1 |
| Ao, Q; Cheng, Q; Hu, Y; Liu, S; Liu, Y; Yang, G; Ye, P; Zhao, J | 1 |
| Gassman, J; Gipson, D; Greene, T; Joy, M; Pinsk, M; Savin, V; Somers, M; Trachtman, H; Vento, S; Wickman, L | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S | 1 |
1 trial(s) available for atorvastatin and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Galactose; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Humans; Infant; Lisinopril; Losartan; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
4 other study(ies) available for atorvastatin and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
[Steroid-resistant focal segmental glomerulosclerosis treated with cascade plasmafiltration and rituximab].
Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Combined Modality Therapy; Diuretics; Drug Resistance; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Male; Mycophenolic Acid; Plasmapheresis; Platelet Aggregation Inhibitors; Rituximab; Salvage Therapy | 2018 |
Atorvastatin improves pathological changes in the aged kidney by upregulating peroxisome proliferator-activated receptor expression and reducing matrix metalloproteinase-9 and transforming growth factor-β1 levels.
Topics: Age Factors; Animals; Atorvastatin; Atrophy; Down-Regulation; Female; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipids; Matrix Metalloproteinase 9; Peroxisome Proliferator-Activated Receptors; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta1; Up-Regulation | 2016 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Atorvastatin; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hypercholesterolemia; Kidney; Male; Nitroprusside; Oxazoles; Phenylephrine; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Renal Circulation; Vasodilation | 2001 |